clarus_final_indentity.jpg
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
10 mai 2022 09h05 HE | Clarus Therapeutics Holdings, Inc.
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2022
04 mai 2022 12h00 HE | Infant Bacterial Therapeutics AB
Message from the CEO IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants, gastrointestinal diseases and probiotics. ...
Infant Bacterial Therapeutics AB (publ), (IBT) delårsrapport 1 januari – 31 mars 2022
04 mai 2022 12h00 HE | Infant Bacterial Therapeutics AB
VD kommenterar IBT:s vision är att bli ett internationellt ledande företag genom utveckling av läkemedel inom områdena för tidigt födda barn, gastrointestinala sjukdomar och probiotika. Vi har nu...
Annual General Meeting of Infant Bacterial Therapeutics
04 mai 2022 10h00 HE | Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Årsstämma i Infant Bacterial Therapeutics
04 mai 2022 10h00 HE | Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2022 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
05 avr. 2022 14h00 HE | Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted...
Kallelse till årsstämma i Infant Bacterial Therapeutics
05 avr. 2022 14h00 HE | Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma onsdagen den 4 maj 2022. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
22157.jpg
Global Alpha Mannosidosis Market to 2030 - Key Drivers and Restraints
05 avr. 2022 06h23 HE | Research and Markets
Dublin, April 05, 2022 (GLOBE NEWSWIRE) -- The "Alpha Mannosidosis Global Market Opportunities And Strategies To 2030, By Therapy Type, Indication, End-User" report has been added to...
Infant Bacterial Therapeutics publishes Annual Report for 2021
31 mars 2022 02h00 HE | Infant Bacterial Therapeutics AB
Press release March 31, 2022 Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section...
Infant Bacterial Therapeutics publicerar årsredovisning för 2021
31 mars 2022 02h00 HE | Infant Bacterial Therapeutics AB
Pressmeddelande 31 mars 2022 Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2021. Årsredovisningen finns tillgänglig på IBTs hemsida,...